YM-905. Treatment of urinary incontinence muscarinic M3 antagonist

Drugs of the Future

Volumn 24, Issue 8, 1999, Pages 871-874

  Mealy, N ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLIC ACID 3 QUINUCLIDINYL ESTER MONOSUCCINATE; 3' (2 AMINO 1 HYDROXYETHYL) 4' FLUOROMETHANESULFONANILIDE; 5 BENZYL 3 (3 MORPHOLINO 1 PHENYLPROPYL) 1,3 OXAZOLIDIN 2 ONE FUMARATE; DARIFENACIN; DULOXETINE; FLURBIPROFEN 4 NITROXYBUTYL ESTER; INAPERISONE; KRP 197; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCLE RELAXANT AGENT; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NITRIC OXIDE DONOR; OXYBUTYNIN; RESINIFERATOXIN; SAREDUTANT; SOLIFENACIN; TEMIVERINE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CONTRACTION; CLINICAL TRIAL; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; URINE INCONTINENCE;

EID: 0344562944     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.08.534524     Document Type: Article

References (7)

1. Takeuchi, M., Naito, R., Yonetoku, Y., Ikeda, K., Isomura, Y. 1,2,3,4-Tetrahydro-2-isoquinolinecarboxylate derivatives: A novel class of selective muscarinic antagonists. III. 213th ACS Natl Meet (April 13-17, San Francisco) 1997, Abst MEDI 046.
2. Takeuchi, M., Naito, R., Hayakawa, M. et al. (Yamanouchi Pharmaceutical Co. Ltd.). Novel quinuclidine derivs. and medicinal compsn. thereof. EP 801067, WO 9620194.
3. Ikeda, K., Kobayashi, S., Suzuki, M., Miyata, K., Takeuchi, M., Yamada, T., Honda, K. Effect of YM905, a novel muscarinic receptor antagonist, on salivary gland and bladder. Jpn J Pharmacol 1998, 76(Suppl. 1): Abst P-442.
4. 3 receptor. FASEB J 1999, 13(4, Part 1): Abst 157.8.
5. Suzuki, M., Ikeda, K., Kobayashi, S., Miyata, K., Takeuchi, M., Yamada, T., Honda, K. Preventive effect of YM905 on stress-induced defecation and diarrhea in rats through the muscarinic receptor antagonism. Jpn J Pharmacol 1998, 76(Suppl. 1): Abst P-443.
6. Kobayashi, S., Ikeda, K., Suzuki, M., Miyata, K., Yamada, T., Honda, K. Antagonist profiles of the novel antimuscarinic agents YM905 and darifenacin in the digestive tract. FASEB J 1999, 13(5, Part 2): Abst 626.4.
7. YM-905 development status. Yamanouchi Pharmaceutical Co., Ltd. Company Communication July 8, 1999.